Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey
Open Access
- 6 October 2015
- journal article
- research article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 16 (15), 6673-6679
- https://doi.org/10.7314/apjcp.2015.16.15.6673
Abstract
Male Breast Cancer: 20 Years Experience of a Tertiary Hospital from the Middle Black Sea Region of Turkey Epidemiology;male breast cancer;pathology;treatment outcome;Turkey; Background: Male breast cancer is a rare neoplasm, and its treatments are based on those of female breast cancer. This study aimed to analyze 20 years of male breast cancer clinical characteristics and treatment results from the Middle Black Sea Region of Turkey. Materials and Methods: A retrospective analysis of 16 male breast cancer patients treated in our tertiary hospital between 1994 and 2014 was performed. Epidemiologic data, tumor characteristics, and treatments were recorded and compared with 466 female breast cancer ((premenopausal; n = 230) + (postmenopausal n = 236)) patients. The 5-year disease-free and overall survival rates were calculated. Results: Male breast cancer constituted 0.1% of all malignant neoplasms in both sexes, 0.2% of all malignant neoplasms in males, and 0.7% of all breast cancers. The mean patient age in this study was $59.8{\pm}9.5$ (39-74) years. The mean time between first symptom and diagnosis was $32.4{\pm}5.3$ (3-60) months. Histology revealed infiltrative ductal carcinoma in 81.3% of patients. The most common detected molecular subtype was luminal A, in 12 (75%) patients. Estrogen receptor rate (93.8%) in male breast cancer patients was significantly higher than that in female breast cancer (70.8% in all females, p = 0.003; 68.2% in postmenopausal females, p = 0.002) patients. Most of the tumors (56.3%) were grade 2. Tumor stage was T4 in 50% of males. The majority (56.3%) of the patients were stage III at diagnosis. Surgery, chemotherapy, radiotherapy and endocrine-therapy were applied to 62.5%, 62.5%, 81.2% and 73.3%, respectively. Loco-regional failure did not occur in any of the cases. All recurrences were metastastic. The 5-year disease-free and overall survival rates in male breast cancer patients were 58% and 68%, respectively. Conclusions: Tumors found in male breast cancer patients were similar in size to tumors found in females, but they advanced to T4 stage more rapidly because of the lack of breast parenchymal tissues. The rate of estrogen receptor expression tended to be higher in male breast cancer patients than in female breast cancer patients. Metastasis is the most important problem in initially non-metastatic male breast cancer patients.
Keywords
This publication has 31 references indexed in Scilit:
- Breast cancer in men in Cote d'Or (France): epidemiological characteristics, treatments and prognostic factorsEuropean Journal of Cancer Care, 2012
- Outcome of non-metastatic male breast cancer: 118 patientsMedical Oncology, 2011
- Imaging Characteristics of Male Breast DiseaseThe Breast Journal, 2010
- Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 casesCritical Reviews in Oncology/Hematology, 2010
- The Diagnostic Accuracy of Mammography and Ultrasound in the Evaluation of Male Breast Disease: A New AlgorithmBreast Care, 2009
- Strategies in treating male breast cancerExpert Opinion on Pharmacotherapy, 2007
- Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Post-mastectomy radiation in male breast cancerRadiotherapy and Oncology, 2002
- Cancer of the male breast: The Turkish experienceJournal of Surgical Oncology, 1993
- Adjuvant Chemotherapy in Males with Cancer of the BreastAmerican Journal of Clinical Oncology, 1987